Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Dasotraline Demonstrates Significant Improvement in Binge Eating Disorder in US PIII Study: Sunovion
July 27, 2018
- Elenbecestat Clears Brain Amyloid, Eisai/Biogen Reports Detailed PII Data
July 26, 2018
- Alunbrig Beats Xalkori in Front-Line NSCLC: Takeda
July 26, 2018
- (Update) Eisai/Biogen Alzheimer’s Drug BAN2401 Slows Cognitive Decline by 30%
July 26, 2018
- Astellas Is Best Pharma Company to Work for: Survey
July 26, 2018
- 2 Major Japan Wholesalers Hook Up on Specialty, Generic Drug Biz
July 25, 2018
- Solasia Grabs China Approval for Antiemetic Patch Drug
July 25, 2018
- Oncologist Lauds Imfinzi as Trailblazer in Stage III Lung Cancer, Eagerly Awaiting OS Data
July 24, 2018
- Sales Reps Required Spontaneous Safety Reports even in Surveys Using Database: Ms Takizawa of Otsuka
July 24, 2018
- Shionogi Ups Earnings Outlook on Xofluza Boost
July 24, 2018
- Daiichi Sankyo’s Herceptin Biosimilar Might Hit Market as Early as November, Breast Cancer Use Also Eyed
July 23, 2018
- Maruho to Increase Information Supply to Non-Dermatologists Using Digital Technology
July 23, 2018
- Wakamoto to Initiate PIII Study of Treatment for Ocular Hypertension
July 23, 2018
- J-TEC Submits Trial Protocol for Autologous Cultured Cartilage in Knee Osteoarthritis Use
July 20, 2018
- Toray, Bonac to Begin US PI Trial of Nucleic Acid for IPF
July 20, 2018
- Subcutaneous Vedolizumab Hits Primary Endpoint in PIII: Takeda
July 20, 2018
- Takeda, Ovid Launching 3 New Studies for Rare Epilepsy Drug
July 20, 2018
- Steep Hikes in Prices of Chinese-Made APIs Could Hit Generic Makers Hard
July 20, 2018
- Fuji Pharma Poised to Develop New Biosimilar in Women’s Health/Acute Care
July 19, 2018
- Belviq Didn’t Increase CV Events in Outcome Study: Eisai
July 19, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…